T
Tania Szado
Researcher at Genentech
Publications - 20
Citations - 2139
Tania Szado is an academic researcher from Genentech. The author has contributed to research in topics: Pertuzumab & Internal medicine. The author has an hindex of 7, co-authored 12 publications receiving 1825 citations.
Papers
More filters
Journal ArticleDOI
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
Luca Gianni,Tadeusz Pienkowski,Young Hyuck Im,L Roman,Ling Ming Tseng,Mei Ching Liu,Ana Lluch,Elżbieta Starosławska,Juan de la Haba-Rodriguez,Seock-Ah Im,Jose Luiz Pedrini,Brigitte Poirier,Paolo Morandi,Vladimir Semiglazov,Vichien Srimuninnimit,Giulia Bianchi,Tania Szado,Jayantha Ratnayake,Graham Ross,Pinuccia Valagussa +19 more
TL;DR: Pertuzumab and trastuzumAB without chemotherapy eradicated tumours in a proportion of women and showed a favourable safety profile, which justifies further exploration in adjuvant trials and support the neoadjuvant approach for accelerating drug assessment in early breast cancer.
Journal ArticleDOI
Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer
Giampaolo Bianchini,Astrid Kiermaier,Giulia Bianchi,Young-Hyuck Im,Tadeusz Pienkowski,Mei Ching Liu,Ling Ming Tseng,Mitch Dowsett,Lila Zabaglo,Sarah Kirk,Tania Szado,Jennifer Eng-Wong,Lukas C. Amler,Pinuccia Valagussa,Luca Gianni +14 more
TL;DR: Conventional HER2 assessment should continue and HER2 remains the only biomarker suitable for patient selection in this population, and PIK3CA exon 9 mutation to lack of sensitivity to HER2-targeted monoclonal antibody treatment, warrant further investigation.
Proceedings ArticleDOI
Abstract S3-2: Neoadjuvant Pertuzumab (P) and Trastuzumab (H): Antitumor and Safety Analysis of a Randomized Phase II Study ('NeoSphere')
L. Gianni,Tadeusz Pienkowski,Y-H Im,L. Roman,L-M Tseng,M-C Liu,A. Lluch-Hernandez,Vladimir Semiglazov,Tania Szado,G. Ross +9 more
TL;DR: These data show the superior antitumor activity of THP and very favorable therapeutic ratio for HP that justify continuing study of the two monoclonals with and without docetaxel in women with HER2- positive early or metastatic breast cancer.
Journal ArticleDOI
A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer.
Y-K. Kang,Sun Young Rha,Pierfrancesco Tassone,Jorge Barriuso,Ron Yu,Tania Szado,Amit Garg,Yung-Jue Bang +7 more
TL;DR: The co-primary endpoints were day 43 pertuzumab serum trough concentration (Cmin) and safety and the pharmacokinetic and safety profiles were similar between arms and treatment was well tolerated.
Proceedings ArticleDOI
S5-1: Neoadjuvant Pertuzumab (P) and Trastuzumab (H): Biomarker Analyses of a 4-Arm Randomized Phase II Study (NeoSphere) in Patients (pts) with HER2−Positive Breast Cancer (BC).
L. Gianni,Giampaolo Bianchini,Astrid Kiermaier,Giulia Bianchi,Y-H Im,Tadeusz Pienkowski,L Roman,M-C Liu,L-M Tseng,Jayantha Ratnayake,Tania Szado,G. Ross,P. Valagussa +12 more
TL;DR: The PI3K mutational status appears to have a relevant role in defining the likelihood of response with all treatments, and is reflected in a different molecular BM profile in ER+ vs ER− tumors, with the IGF1R membrane score being correlated with ER − tumors.